人诺如病毒疫苗及治疗药物的研究进展  

Research progress on vaccines and therapeutic drugs for human norovirus

作　　者：张巧玲(综述) 陈勇 蒋琳(审校) Zhang Qiaoling;Chen Yong;Jiang Lin(No.4 Research Laboratory,Lanzhou Institute of Biological Products Co.,Ltd.,Lanzhou 730046,China)

机构地区：[1]兰州生物制品研究所有限责任公司第四研究室,730046

出　　处：《国际生物制品学杂志》2019年第5期239-246,共8页International Journal of Biologicals

摘　　要：诺如病毒(norovirus,NoV)是引起急性胃肠炎的主要病原体之一,可以感染所有年龄段的人群。目前针对NoV引发的疾病尚无有效的治疗和预防手段,对于易感人群以及群发性感染,制定预防策略(包括疫苗)是必要的。利用NoV衣壳蛋白VP1以及VP1 P区域自我组装形成的病毒样颗粒是NoV疫苗的主要研究方向,通过基因工程技术设计的多种相关疫苗已在不同系统中表达,临床试验证明部分疫苗具有良好的免疫原性。此外,NoV与其他肠道病原体如轮状病毒的联合疫苗也具有良好的前景。此文重点介绍目前处于临床前以及临床研究的NoV疫苗以及NoV相关疾病的治疗药物。Norovirus(NoV)is one of the leading pathogens causing epidemic acute gastroenteritis affecting people of all ages.There is currently no effective treatment or prevention for diseases caused by NoV.It is necessary to develop preventive strategies(including vaccines)for susceptible populations and mass infections.Virus-like particle formed by NoV capsid protein VP1 and the protruding(P)domain of VP1 has become the main vaccine development focus.Vaccine candidates produced by bioengineering technologies have been expressed in different expressing systems and some proven to be immunogenic in clinical trials.Combined vaccines of NoV and other enteric pathogens such as rotavirus also appear to be promising.This article discusses NoV vaccines in pre-clinical and clinical researches as well as clinical drugs for NoV-associated disease.

关 键 词：诺罗病毒 病毒样颗粒 疫苗 药物 临床试用 

分 类 号：S85[农业科学—兽医学]